Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
What Analysts Are Saying About Novo Nordisk Stock
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00, and a low estimate of $105.00. A 8.65% drop is evident in the current ...